Skip to content

German Centre for Cardiovascular Research Cardiomyopathy Register

DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum für Herz- Und Kreislauf-Forschung (DZHK)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02187263
Acronym
TORCH
Enrollment
2300
Registered
2014-07-10
Start date
2014-12-31
Completion date
2017-12-31
Last updated
2016-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocarditis, Amyloidosis, Arrhythmogenic Right Ventricular Cardiomyopathies, Dilated Cardiomyopathies, Hypertrophic Cardiomyopathies, Left Ventricular Myocardial Noncompaction Cardiomyopathy

Keywords

hereditary cardiomyopathy,, inflammatory cardiomyopathy,, registry,, biomaterial,, clinical trial, Patients

Brief summary

This is a joint project by Heidelberg University and Greifswald University. Our objective is to establish an unique national multi-center registry and biobank of well phenotyped patients with non-ischemic cardiomyopathies (CMP) including in depth clinical, molecular and omics-based phenotyping to serve as: 1. central hub for clinical outcome studies. 2. joint resource for diagnostic and therapeutic trials. 3. common biomaterial bank. 4. resource for detailed molecular analyses on patients' biomaterials and patient specific model systems.

Detailed description

The following basic research projects, called modules, will be tied to and rely on the recruitment of CMP patients and the infrastructure provided by TORCH: * Well phenotyped patients will be the starting point for comprehensive next-generation genotyping, leading to advanced estimates of genotype-phenotype relationship and its clinical impact. * Functional analysis of novel genomic loci and their related molecular pathways will be based on our established in-vitro (e.g. iPS cells, yeast two hybrid) and in-vivo (e.g. zebrafish and mice) model systems. * The integrated analysis of viral load and replication, inflammation, genotype and clinical variables will define risk variables for inflammatory and hereditary CMP. * By longitudinal follow-up of patients, the role of genetic, epigenetic, metabolic, molecular biomarkers and histopathology for diagnosis and out-come prediction will be defined on a national level. The registry will also facilitate investigator initiated clinical trials.

Interventions

None listed

Sponsors

Kerckhoff Klinik
CollaboratorOTHER
University Hospital Goettingen
CollaboratorOTHER
University of Hamburg-Eppendorf
CollaboratorOTHER
University of Kiel
CollaboratorOTHER
University of Luebeck
CollaboratorOTHER
Mainz University
CollaboratorOTHER
University Medical Centre Mannheim
CollaboratorUNKNOWN
Ludwig-Maximilians - University of Munich
CollaboratorOTHER
Medical University of Hannover
CollaboratorOTHER
Department for Community Medicine, University Medicine Greifswald
CollaboratorUNKNOWN
Goethe University
CollaboratorOTHER
Charite University, Berlin, Germany
CollaboratorOTHER
University Hospital Greifswald
CollaboratorOTHER
German Heart Institute
CollaboratorOTHER
ISAR Klinikum Munich
CollaboratorINDUSTRY
Heidelberg University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Patients with primary non-ischemic cardiomyopathies including hereditary and inflammatory dilated cardiomyopathy, left ventricular non-compaction cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and acute myocarditis.

Exclusion criteria

* Preexisting other cardiac diseases such as significant valvular, ischemic or pericardial disease; Severe arterial hypertension; Primary pulmonary artery hypertension; Chronic advanced disorders; History of treatment with cardiotoxic agents and chest radiation; Drug and alcohol abuse; Patients \<18 and \>79 years of age; Life expectancy less than 1 year due to non-cardiac comorbidity

Design outcomes

Primary

MeasureTime frame
Time to Disease Progression12 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 31, 2026